China Medical System Holdings Ltd (867):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:China Medical System Holdings Ltd (867) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7985
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
China Medical System Holdings Ltd (CMS) is a pharmaceutical service provider that markets, promotes, and sells prescription drugs to all therapeutic departments in hospitals. The company offers products such as deanxit, ursofalk, augentropfen stulln mono eye-drops, exacin, xinhuosu, salofalk, bioflor, ganfule, and cystistat. It also offers shaduolika, yinuoshu, xidakang and astragalus. CMS partners include AstraZenca, H.Lundbeck A/S, Dr.Falk Pharma Gmbh, Bicodex, Pharma Stulln Gmbh, DKSH. Nordmark Arzneimittel GmbH & Co. KG. It has pharmaceutical manufacturing sites in Shenzhen, Hunan and Hebei Province. The company serves physicians, patients and specialty pharmaceutical companies. CMS is headquartered in Shenzhen, China.

China Medical System Holdings Ltd (867) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China Medical System Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 9
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
China Medical System Acquires Six Products from Venus Pharma 12
China Medical System Acquires Rights to Imdur from AstraZeneca 13
China Medical System to Acquire Combizym and Hirudoid from Dksh for USD79.6 Million 14
China Medical System Acquires Rights to Lamisil and Parlodel from Novartis 15
China Medical System Acquires Product Rights from Pharma Stulln for USD13.6 Million 17
China Medical System Acquires Rights to XiDaKang from Kangzhe Guangming 18
Venture Financing 19
Acticor Biotech Raises USD17.7 Million in Series B Financing 19
Partnerships 21
Destiny Pharma Enters into Agreement with China Medical System 21
Licensing Agreements 22
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 22
China Medical System Enters into Licensing Agreement with AstraZeneca 23
China Medical System Enters into Licensing Agreement with Faron Pharma 24
China Medical System Enters Into Licensing Agreement With Biocodex For Stimol 25
Equity Offering 26
Destiny Pharma Raises USD2.4 Million in Private Placement of Shares 26
Acquisition 27
China Medical System Acquires 52% Stake in Hebei Xili Xinglong Pharma 27
China Medical System Holdings Ltd – Key Competitors 28
China Medical System Holdings Ltd – Key Employees 29
China Medical System Holdings Ltd – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Corporate Communications 31
Oct 18, 2017: China Medical System Holdings: Further Announcment in Relation to Resignation of Ms. Sa Manlin as Executive Director 31
Oct 17, 2017: China Medical System Holdings: Resignation of Executive Director 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Medical System Holdings Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
China Medical System Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 9
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
China Medical System Acquires Six Products from Venus Pharma 12
China Medical System Acquires Rights to Imdur from AstraZeneca 13
China Medical System to Acquire Combizym and Hirudoid from Dksh for USD79.6 Million 14
China Medical System Acquires Rights to Lamisil and Parlodel from Novartis 15
China Medical System Acquires Product Rights from Pharma Stulln for USD13.6 Million 17
China Medical System Acquires Rights to XiDaKang from Kangzhe Guangming 18
Acticor Biotech Raises USD17.7 Million in Series B Financing 19
Destiny Pharma Enters into Agreement with China Medical System 21
CMS Medical Enters into Licensing Agreement with Can-Fite BioPharma 22
China Medical System Enters into Licensing Agreement with AstraZeneca 23
China Medical System Enters into Licensing Agreement with Faron Pharma 24
China Medical System Enters Into Licensing Agreement With Biocodex For Stimol 25
Destiny Pharma Raises USD2.4 Million in Private Placement of Shares 26
China Medical System Acquires 52% Stake in Hebei Xili Xinglong Pharma 27
China Medical System Holdings Ltd, Key Competitors 28
China Medical System Holdings Ltd, Key Employees 29
China Medical System Holdings Ltd, Other Locations 30

List of Figures
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
China Medical System Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
China Medical System Holdings Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[China Medical System Holdings Ltd (867):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Formosa Laboratories Inc (4746)-製薬・医療分野:企業M&A・提携分析
    Summary Formosa Laboratories Inc (Formosa) is a healthcare products provider that develops ingredients. The company develops and markets active pharmaceutical ingredients and UV filters. Its active pharmaceutical ingredients comprise anticancers, cholesterol and phosphate binders, MRI enhancing agen …
  • Rogers Communications, Inc.:企業の戦略・SWOT・財務情報
    Rogers Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rogers Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • RussNeft Oil Co (RNFT):石油・ガス:M&Aディール及び事業提携情報
    Summary RussNeft Oil Company (RussNeft) is an oil and gas company that produces, refines and distributes crude oil, gas and petroleum products. The company operates through its business divisions such as geologic exploration and reserves, production, marketing, research center, transport and gas pro …
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a subsidiary of National Institutes of Health, is a research institute that conducts and supports laboratory research, clinical trials, and epidemiological studies. The institute conducts research in the …
  • Macmahon Holdings Ltd:企業の戦略・SWOT・財務分析
    Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Consolidated Edison, Inc.:企業の戦略・SWOT・財務分析
    Consolidated Edison, Inc. - Strategy, SWOT and Corporate Finance Report Summary Consolidated Edison, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Oxford Immunotec Ltd:企業の製品パイプライン分析2018
    Summary Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.T …
  • AS Kevelt-製薬・医療分野:企業M&A・提携分析
    Summary AS Kevelt (Kevelt), a subsidiary of Pharmsynthez is a healthcare company that develops, manufactures and markets drug products. The company offers products which include concentrate solutions for infusion, endocervical gel, eye drops and other solutions. It also offers sub-contracting and di …
  • Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • Gradalis Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals Inc, is a biopharmaceutical company that provides development and commercialization of therapies for the treatment of cancer. The company’s developmental pipeline comprises of candidates for various cancer indications which include ovar …
  • Pental Limited (PTL):企業の財務・戦略的SWOT分析
    Pental Limited (PTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Westar Energy Inc (WR):電力:M&Aディール及び事業提携情報
    Summary Westar Energy, Inc. (Westar Energy) is a vertically integrated energy utility that generates, transmits and distributes electricity. The company owns and operates a generation portfolio of coal-fired, nuclear, natural gas-based, renewable and diesel-based power plants. It also procures elect …
  • China Chemical & Pharmaceutical Co Ltd (1701):企業の財務・戦略的SWOT分析
    China Chemical & Pharmaceutical Co Ltd (1701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Novotech (Australia) Pty Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Novotech (Australia) Pty Ltd (Novotech) is a contract research organization that offers clinical development services. The organization’s services include clinical trials, data management, biostatistics analysis, audits, regulatory affairs, medical writing, site management and commercializat …
  • Oxford Biodynamics Plc:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Biodynamics Plc (Oxford Biodynamics) is a developer of biomarker discovery platform. The company concentrates on research in detection, monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology, metabolic, inflammatory, cardiovascular and neu …
  • The Wharf (Holdings) Limited
    The Wharf (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary The Wharf (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Erytech Pharma SA (ERYP):企業の財務・戦略的SWOT分析
    Summary Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are …
  • Mindray Medical International Ltd-医療機器分野:企業M&A・提携分析
    Summary Mindray Medical International Ltd (Mindray) is a medical device company. Its major products include multi-parameter patient monitors, telemetry monitoring system, defibrillator, anesthesia machine, surgical lights, ceiling supply units, veterinary monitoring systems, hematology analyzer and …
  • Gramercy Property Trust:企業のM&A・事業提携・投資動向
    Gramercy Property Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gramercy Property Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆